Recipharm has signed a partnership agreement with Follicum AB to formulate and produce the drug candidate FOL-005 for a clinical trial. Recipharm will also develop and validate the analytical methods required. In preclinical studies, FOL-005 has both stimulated and inhibited hair growth effectively even at low doses.   “Preparations for the clinical study are well under way, and we have now established ties with partners that we feel confident in. Recipharm is successful in its field and has a...